NICE (National Institute for Health and Clinical Excellence) tackles age and lifestyle in NHS access policies
This article was originally published in Clinica
Executive Summary
The National Institute for Health and Clinical Excellence (NICE) has published draft guidelines on the social value judgements that impinge on the development of its guidance. The final document will, together with scientific considerations, feed into its own assessment processes, and will not in itself constitute guidance to the wider NHS.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.